These results revealed circEGFR is a promising biomarker for TNBC diagnosis, therapeutic and prognosis.
CircEGFR reduces the sensitivity of pirarubicin and regulates the malignant progression of triple-negative breast cancer via the miR-1299/EGFR axis.